Evidence map›Paper›PMID 41794039›Full record

ArticleCell reports. Medicine2026

Proteogenomic characterization delineates clinically relevant subtypes of advanced differentiated thyroid cancer.

Tingting Zhang, Wangpeng Cui, Haitao Tang, Cenkai Shen, Yan Zhang, Yaoting Sun, Yan Zhou, Chentian Shen, Huajun Xu, Chenyi Wang and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Tingting ZhangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Wangpeng CuiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Haitao TangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Cenkai ShenDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yan ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Pathology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yaoting SunWestlake Center for Intelligent Proteomics, School of Life Sciences, Westlake University, Hangzhou 310024, China.
Yan ZhouWestlake Center for Intelligent Proteomics, School of Life Sciences, Westlake University, Hangzhou 310024, China.
Chentian ShenDepartment of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
Huajun XuDepartment of Otolaryngology-Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
Chenyi WangDepartment of Ultrasound, China-Japan Friendship Hospital, Beijing 100029, China.
Wenyang DingShanghai OE Biotech Co., Ltd, Shanghai 201112, China.
Fuxing ZhengShanghai OE Biotech Co., Ltd, Shanghai 201112, China.
Tiansheng XuShanghai OE Biotech Co., Ltd, Shanghai 201112, China.
Chuqiao LiuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yuxin DuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhiyan LiuDepartment of Pathology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
Yulong WangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Naisi HuangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaoqi MaoDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Dongmei JiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xing SunDepartment of General Surgery, Shanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. Electronic address: xingsun@hotmail.com.
Qinghai JiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: jq_hai@126.com.
Wenjun WeiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: wenjunweifdu@163.com.
Yu WangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: neck130@sina.com.
Xiao ShiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: xshi11@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced differentiated thyroid cancer (DTC) is characterized by limited therapeutic options and unfavorable prognosis. To address this, we conduct proteogenomic analysis of 113 advanced DTCs, identifying three molecularly distinct subtypes: canonical, stromal, and immunogenic. These subtypes exhibit differences in driver mutations, histopathological features, and clinical outcomes. Based on their unique biology, we suggest distinct therapeutic strategies for each subtype. To facilitate clinical application, we develop a machine learning classifier that accurately predicts these subtypes using routinely available gene mutation and digital pathology data. The biological relevance of this classification is further confirmed in an independent cohort analyzed by single-cell and spatial transcriptomics. Moreover, analysis of a real-world cohort of patients receiving various systemic therapies provides preliminary clinical evidence supporting the potential utility of this subtyping framework for informing treatment decisions. Collectively, this study provides a rationale and a practical tool for future exploration of personalized treatment in advanced DTC.

Indexed as

ProteogenomicsThyroid NeoplasmsFemaleHumansMachine LearningMaleMiddle AgedMutationPrognosisadvanced-stage diseasedifferentiated thyroid cancerimmunotherapymolecular subtypingprecision treatmentproteogenomicsradioactive iodinetargeted therapy

Identifiers

PMID41794039
PMCPMC13006413

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.